全文获取类型
收费全文 | 476篇 |
免费 | 26篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 6篇 |
妇产科学 | 3篇 |
基础医学 | 113篇 |
口腔科学 | 1篇 |
临床医学 | 53篇 |
内科学 | 145篇 |
皮肤病学 | 4篇 |
神经病学 | 12篇 |
特种医学 | 10篇 |
外科学 | 41篇 |
预防医学 | 44篇 |
眼科学 | 4篇 |
药学 | 35篇 |
肿瘤学 | 29篇 |
出版年
2023年 | 9篇 |
2022年 | 5篇 |
2021年 | 36篇 |
2020年 | 17篇 |
2019年 | 22篇 |
2018年 | 21篇 |
2017年 | 11篇 |
2016年 | 10篇 |
2015年 | 8篇 |
2014年 | 15篇 |
2013年 | 18篇 |
2012年 | 27篇 |
2011年 | 35篇 |
2010年 | 11篇 |
2009年 | 13篇 |
2008年 | 22篇 |
2007年 | 24篇 |
2006年 | 25篇 |
2005年 | 24篇 |
2004年 | 16篇 |
2003年 | 14篇 |
2002年 | 11篇 |
2001年 | 6篇 |
2000年 | 5篇 |
1999年 | 2篇 |
1997年 | 1篇 |
1993年 | 1篇 |
1992年 | 8篇 |
1991年 | 18篇 |
1990年 | 7篇 |
1989年 | 5篇 |
1988年 | 6篇 |
1987年 | 10篇 |
1986年 | 1篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1979年 | 4篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1973年 | 4篇 |
1972年 | 5篇 |
1971年 | 7篇 |
1969年 | 2篇 |
1968年 | 1篇 |
排序方式: 共有503条查询结果,搜索用时 21 毫秒
1.
2.
Aleksandr M. Filimonov Oleg A. Rogozin Denis G. Firsov Yulia O. Kuzminova Semen N. Sergeev Alexander P. Zhilyaev Marat I. Lerner Nikita E. Toropkov Alexey P. Simonov Ivan I. Binkov Ilya V. Okulov Iskander S. Akhatov Stanislav A. Evlashin 《Materials》2021,14(1)
The particle size distribution significantly affects the material properties of the additively manufactured parts. In this work, the influence of bimodal powder containing nano- and micro-scale particles on microstructure and materials properties is studied. Moreover, to study the effect of the protective atmosphere, the test samples were additively manufactured from 316L stainless steel powder in argon and nitrogen. The samples fabricated from the bimodal powder demonstrate a finer subgrain structure, regardless of protective atmospheres and an increase in the Vickers microhardness, which is in accordance with the Hall-Petch relation. The porosity analysis revealed the deterioration in the quality of as-built parts due to the poor powder flowability. The surface roughness of fabricated samples was the same regardless of the powder feedstock materials used and protective atmospheres. The results suggest that the improvement of mechanical properties is achieved by adding a nano-dispersed fraction, which dramatically increases the total surface area, thereby contributing to the nitrogen absorption by the material. 相似文献
3.
4.
5.
Irina V. Poddubnaya Sergey M. Alekseev Kamil D. Kaplanov Les M. Lukavetskyy Grigoriy B. Rekhtman Tuphan K. Dolai V. Satya Suresh Attili Carlos D. Bermúdez Aleksandr A. Isaev Ekaterina V. Chernyaeva Roman A. Ivanov 《Hematological oncology》2020,38(1):67-73
BCD-020 is a proposed rituximab biosimilar, which has shown high similarity to rituximab in quality and nonclinical studies in vitro and in vivo. International multicenter clinical trial was conducted to compare efficacy and safety of BCD-020 and reference rituximab in adult (older than 18 years) patients with indolent lymphomas (follicular lymphoma grade 1-2, splenic marginal zone lymphoma, and nodal marginal zone lymphoma). Pharmacokinetics, pharmacodynamics, and immunogenicity were also studied. Patients with no previous biologic treatment for lymphoma were randomly assigned 1:1 to receive BCD-020 or comparator 375 mg/m2 for 4 weeks. Primary study outcome was day 50 overall response rate defined as complete or partial remission. Equivalence range was −20% to 20% for 95% CI for overall response rates difference. Secondary outcomes included adverse events, pharmacokinetics, pharmacodynamics, and immunogenicity. One hundred seventy-four patients were enrolled, 89 in BCD-020 arm and 85 in comparator arm. The overall response rate was 44.71% in BCD-020 arm and 41.89% in comparator arm. Limits of 95% confidence interval (CI) for difference of overall response rates between arms were (−12.62%-18.24%) showing equivalent efficacy. Sixty-one (68.54%) and 59 (69.41%) patients had at least one adverse event in BCD-020 arm or comparator arm, respectively. No unexpected adverse reactions were reported. Antidrug antibodies with no neutralizing activity were detected in two patients in comparator arm on day 14 further declining below detection threshold. Rituximab concentrations had equivalent pattern after intravenous administration of both drugs. Both drugs caused depletion of B-cells without significant influence on other blood cell lineages. In this study, we showed equivalent efficacy of BCD-020 and reference rituximab when used in patients with CD20-positive indolent lymphomas. We also confirmed pharmacokinetic equivalence of BCD-020 and reference rituximab. Safety profile, pharmacodynamics, and immunogenicity of BCD-020 were also comparable with those of reference rituximab. 相似文献
6.
Deepa Jagadeesh MD Navneet S. Majhail MD Yizeng He MS Kwang W. Ahn PhD Carlos Litovich MS Sairah Ahmed MD Mahmoud Aljurf MD Ulrike Bacher MD Sherif M. Badawy MD Nelli Bejanyan MD Mitchell Cairo MD Jan Cerny MD Narendranath Epperla MD Nosha Farhadfar MD César O. Freytes MD Robert Peter Gale MD Bradley Haverkos MD Nasheed Hossain MD David Inwards MD Rammurti T. Kamble MD Vaishalee P. Kenkre MD Hillard M. Lazarus MD Aleksandr Lazaryan MD Lazaros Lekakis MD Matthew Mei MD Hemant S. Murthy MD Alberto Mussetti MD Sunita Nathan MD Taiga Nishihori MD Richard F. Olsson MD Praveen Ramakrishnan Geethakumari MD Bipin N. Savani MD Jean A. Yared MD Timothy S. Fenske MD Mohamed A. Kharfan-Dabaja MD Anna Sureda MD Mehdi Hamadani 《Cancer》2020,126(10):2279-2287
7.
Otavio Berwanger Renato D. Lopes Diogo D.F. Moia Francisco A. Fonseca Lixin Jiang Shaun G. Goodman Stephen J. Nicholls Alexander Parkhomenko Oleg Averkov Carlos Tajer Germán Malaga Jose F.K. Saraiva Helio P. Guimaraes Pedro G.M. de Barros e Silva Lucas P. Damiani Renato H.N. Santos Denise M. Paisani Tamiris A. Miranda Jose C. Nicolau 《Journal of the American College of Cardiology》2019,73(22):2819-2828
BackgroundThe efficacy of ticagrelor in the long-term post–ST-segment elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remains uncertain.ObjectivesThe purpose of this study was to evaluate the efficacy of ticagrelor when compared with clopidogrel in STEMI patients treated with fibrinolytic therapy.MethodsThis international, multicenter, randomized, open-label with blinded endpoint adjudication trial enrolled 3,799 patients (age <75 years) with STEMI receiving fibrinolytic therapy. Patients were randomized to ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300- to 600-mg loading dose, 75 mg daily thereafter). The key outcomes were cardiovascular mortality, myocardial infarction, or stroke, and the same composite outcome with the addition of severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events at 12 months.ResultsThe combined outcome of cardiovascular mortality, myocardial infarction, or stroke occurred in 129 of 1,913 patients (6.7%) receiving ticagrelor and in 137 of 1,886 patients (7.3%) receiving clopidogrel (hazard ratio: 0.93; 95% confidence interval: 0.73 to 1.18; p = 0.53). The composite of cardiovascular mortality, myocardial infarction, stroke, severe recurrent ischemia, transient ischemic attack, or other arterial thrombotic events occurred in 153 of 1,913 patients (8.0%) treated with ticagrelor and in 171 of 1,886 patients (9.1%) receiving clopidogrel (hazard ratio: 0.88; 95% confidence interval: 0.71 to 1.09; p = 0.25). The rates of major, fatal, and intracranial bleeding were similar between the ticagrelor and clopidogrel groups.ConclusionAmong patients age <75 years with STEMI, administration of ticagrelor after fibrinolytic therapy did not significantly reduce the frequency of cardiovascular events when compared with clopidogrel. (Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis [TREAT]; NCT02298088) 相似文献
8.
Shernan G. Holtan Lin Zhang Todd E. DeFor Nelli Bejanyan Mukta Arora Armin Rashidi Aleksandr Lazaryan Florence Kotiso Bruce R. Blazar John E. Wagner Claudio G. Brunstein Margaret L. MacMillan Daniel J. Weisdorf 《Biology of blood and marrow transplantation》2019,25(9):1884-1889
Graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) represents complete, ideal recovery after allogeneic hematopoietic cell transplantation (HCT). However, as originally proposed, this composite endpoint does not account for the possibility that HCT complications may improve after treatment. To more accurately estimate survival with response to GVHD and relapse after HCT, we developed a dynamic multistate GRFS (dGRFS) model with outcomes data from 949 patients undergoing their first allogeneic HCT for hematologic malignancy at the University of Minnesota. Because some patients were successfully treated for GVHD and relapse, dGRFS was higher than the originally defined time-to-event GRFS at 1 year (37.0 versus 27.6%) through 4 years (37.4% versus 22.2%). Mean survival without failure events was .52 years (95% confidence interval, .45 to .58 year) greater in dGRFS compared with the originally defined GRFS. Patient age (P< .001), disease risk (P < .001), conditioning intensity (P = .007), and donor type (P = .003) all significantly influenced dGRFS. The multistate model of dGRFS closely estimates the continuing and prevalent severe morbidity and mortality of allogeneic HCT. To serve the greater HCT community in more accurately modeling recovery from transplantation, we provide our R code for determination of dGRFS with annotations in Supplementary Materials. 相似文献
9.
Erica Dahl Warlick Todd E. DeFor Nelli Bejanyan Shernan Holtan Margaret MacMillan Bruce R. Blazar Kathryn Dusenbery Mukta Arora Veronika Bachanova Sarah Cooley Aleksandr Lazaryan Philip McGlave Jeffrey S Miller Armin Rashidi Arne Slungaard Gregory Vercellotti Celalettin Ustun Claudio Brunsein Daniel Weisdorf 《Biology of blood and marrow transplantation》2019,25(1):56-62
Reduced-intensity conditioning (RIC) extends the curative potential of allogeneic hematopoietic cell transplantation (HCT) to patients with hematologic malignancies unable to withstand myeloablative conditioning. We prospectively analyzed the outcomes of 292 consecutive patients, median age 58 years (range, 19 to 75) with hematologic malignancies treated with a uniform RIC regimen of cyclophosphamide, fludarabine, and total body irradiation (200 cGy) with or without antithymocyte globulin and cyclosporine and mycophenolate mofetil graft-versus-host disease (GVHD) prophylaxis followed by allogeneic HCT at the University of Minnesota from 2002 to 6. Probability of 5-year overall survival was 78% for patients with indolent non-Hodgkin lymphoma, 53% for chronic myelogenous leukemia, 55% for Hodgkin lymphoma, 40% for acute myelogenous leukemia, 37% for myelodysplastic syndrome, 29% for myeloma, and 14% for myeloproliferative neoplasms. Corresponding outcomes for relapse were 0%, 13%, 53%, 37%, 39%, 75%, and 29%, respectively. Disease risk index (DRI) predicted both survival and relapse with superior survival (64%) and lowest relapse (16%) in those with low risk score compared with 24% survival and 57% relapse in those with high/very-high risk scores. Recipient cytomegalovirus (CMV)-positive serostatus was protective from relapse with the lowest rates in those also receiving a CMV-positive donor graft (29%). The cumulative incidence of 2-year nonrelapse mortality was 26% and was lowest in those receiving a matched sibling graft at 21%, with low (21%) or intermediate (18%) HCT-specific comorbidity index, and was similar across age groups. The incidence of grades II to IV acute GVHD was 43% and grades III to IV 27%; the highest rates were found in those receiving an unrelated donor (URD) peripheral blood stem cell (PBSC) graft, at 50%. Chronic GVHD at 1 year was 36%.Future approaches incorporating alternative GVHD prophylaxis, particularly for URD PBSC grafts, and targeted post-transplant antineoplastic therapies for those with high DRI are indicated to improve these outcomes. 相似文献
10.